A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Actinic Keratosis Clinical Trial

Official title:

Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02654769
• Other study ID #: 094-8151-301
• Status: Completed
• Phase: Phase 3
• Start date: February 2015
• Est. completion date: September 2015

Study information

• Verified date: April 2020
• Source: Actavis Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.05% to Picato gel, 0.05% and to establish the superiority of the efficacy of these two products over the vehicle gel in the treatment of Actinic Keratosis (AK) on the trunk or extremities.

Description:

Picato® (ingenol mebutate) gel is the first and only ingenol mebutate product approved by the FDA in 2012 for the topical treatment of AK(s) on the face and scalp (0.015% formulation) and on the trunk and extremities (0.05% formulation). A generic ingenol mebutate gel, 0.05% has been developed for the topical treatment of clinically typical, visible, and discrete non-hyperkeratotic, non-hypertrophic AK lesions of the trunk or extremities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 441
• Est. completion date: September 2015
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 95 Years

Eligibility

Inclusion Criteria:

• Subject was a male or non-pregnant female 18 years of age or older

• Subject provided written informed consent.

• Subject was willing and able to apply the test article as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.

• Subject had a clinical diagnosis of AK at Baseline with at least four (4), but no more than eight (8), visible and discrete non-hyperkeratotic, non-hypertrophic AK lesions, each at least 4 mm in diameter, within a contiguous 25 cm2 treatment area ("the Treatment Area") on the trunk or extremities.

• Subject was in good general health and free of any disease state or physical condition that might have impaired evaluation of AK lesions or which, in the investigator's opinion, exposed the subject to an unacceptable risk by study participation.

• Females must have been post-menopausal , surgically sterile , or have used an effective method of birth control , with a negative urine pregnancy test (UPT) at the Baseline Visit.

Exclusion Criteria:

• Subject was pregnant, lactating, or was planning to become pregnant during the study.

• Subject was currently enrolled in an investigational drug or device study.

• Subject used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.

• Subject had hyperkeratotic, hypertrophic, or large mat-like AKs (e.g., AK >1 cm2 in size) within the contiguous 25 cm2 Treatment Area.

• Subject had more than eight (8) AKs, independent of size, within the contiguous 25 cm2 Treatment Area.

• Subject had the need or planned to be exposed to artificial tanning devices or excessive sunlight during the trial.

• Subject was immunosuppressed (e.g., HIV, systemic malignancy, graft host disease, etc.)

• Subject had experienced an unsuccessful outcome from previous ingenol mebutate therapy (an unsuccessful outcome was defined as after a reasonable therapeutic trial with no compliance issues and the topical drug did not work).

• Subject had a history of sensitivity to any of the ingredients in the test articles (see Section 9.4.2).

• Subject used topical creams, lotions, or gels of any kind within the selected Treatment Area within one (1) day prior to entry into the study.

• Subject used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.

• Subject had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit.

• Subject used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within one (1) month prior to the Baseline Visit.

• Subject had dermatologic procedures or surgeries such as laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B (UVB) therapy, chemical peels, or dermabrasion on the selected Treatment area (trunk or extremities) within six (6) months prior to the Baseline Visit.

• Subject had lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected Treatment Area (trunk or extremities).

• Subject had any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the test article or required the use of interfering topical, systemic, or surgical therapy.

• Subject had any condition which, in the investigator's opinion, would have made it unsafe or precluded the subject's ability to fully participate in this research study.

• Subject was unable to communicate or cooperate with the investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.

• Subject was known to be noncompliant or was unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

• Subject had been previously enrolled in the same study.

Related Conditions & MeSH terms

• Actinic Keratosis
• Keratosis
• Keratosis, Actinic

Intervention

Drug:
• Ingenol Mebutate (Picato®)
Brand product
• Generic Ingenol Mebutate
Generic formulated to have the same therapeutic effect of the brand
• Vehicle Foam
It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.

Locations

Country	Name	City	State
United States	Altman Dermatology Associates	Arlington Heights	Illinois
United States	DermResearch, Inc.Austin	Austin	Texas
United States	The Center for Clinical and Cosmetic Research	Aventura	Florida
United States	Northwest Clinical Trials, Inc.	Boise	Idaho
United States	Shideler Clinical Research Center	Carmel	Indiana
United States	Christie Clinic, LLC	Champaign	Illinois
United States	Center for Dermatology Clinical Research, Inc	Fremont	California
United States	Greenville Dermatology, LLC	Greenville	South Carolina
United States	Bettencourt Skin Center	Henderson	Nevada
United States	Dermatology Consulting Services	High Point	North Carolina
United States	The Center for Skin Research	Houston	Texas
United States	Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana
United States	Dermatology Associates of Knoxville, PC	Knoxville	Tennessee
United States	Savin Medical Group Research Center	Miami Lakes	Florida
United States	Union Square Dermatology	New York	New York
United States	Virginia Clinical Research	Norfolk	Virginia
United States	Tory P. Sullivan, M.D., P.A.	North Miami Beach	Florida
United States	The Indiana Clinical Trials Center	Plainfield	Indiana
United States	SD Sports Medicine & Family Health Center	San Diego	California
United States	Moore Clinical Research, Inc.	Tampa	Florida
United States	Omega Medical Research, 400 Bald Hill Road, Warwick, RI 02886	Warwick	Rhode Island
United States	PMG Research of Winston-Salem, LLC	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Actavis Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Efficacy Outcome Measure	Percentage of subjects in the PP population in each treatment group with complete clearance of AK lesions. Complete clearance was defined as having no (zero) clinically visible AK lesions in the Treatment Area at the Week 8 visit.	8 weeks
Secondary	The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.		8 weeks